Get the Stockscreener App
127.00
0.02%
-0.02
After Hours:
126.99
-0.01
-0.01%
Intra Cellular Therapies Inc stock is traded at $127.00, with a volume of 2.29M.
It is down -0.02% in the last 24 hours and up +52.13% over the past month.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
See More
Previous Close:
$127.02
Open:
$126.91
24h Volume:
2.29M
Relative Volume:
1.11
Market Cap:
$13.49B
Revenue:
$612.78M
Net Income/Loss:
$-86.37M
P/E Ratio:
-145.98
EPS:
-0.87
Net Cash Flow:
$-62.91M
1W Performance:
-0.06%
1M Performance:
+52.13%
6M Performance:
+62.61%
1Y Performance:
+85.70%
1-Day Range:
$126.91
$127.24
1-Week Range:
$126.91
$127.61
52-Week Range:
$62.78
$128.00
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Name
Intra Cellular Therapies Inc
Sector
Phone
(646) 440-9333
Address
135 ROUTE 202/206, BEDMINSTER, NY
Compare ITCI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
127.00 | 13.49B | 612.78M | -86.37M | -62.91M | -0.87 |
|
ZTS
Zoetis Inc
|
172.71 | 77.92B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.70 | 43.43B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
HLN
Haleon Plc Adr
|
9.57 | 43.27B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.84 | 20.21B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
153.29 | 15.52B | 2.24B | 385.90M | 440.10M | 3.73 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-06-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-11-23 | Initiated | TD Cowen | Outperform |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Aug-22-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-22-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Initiated | Goldman | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| Dec-15-20 | Initiated | BofA Securities | Buy |
| Dec-10-20 | Initiated | Goldman | Buy |
| Feb-20-20 | Initiated | Evercore ISI | Outperform |
| Jan-31-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-24-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-12-19 | Initiated | Jefferies | Buy |
| Feb-26-18 | Initiated | JP Morgan | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Nov-08-17 | Upgrade | SunTrust | Hold → Buy |
| Sep-07-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-30-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Aug-24-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Aug-23-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-02-17 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| May-02-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| May-01-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-16 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-29-16 | Downgrade | SunTrust | Buy → Neutral |
View All
Intra Cellular Therapies Inc Stock (ITCI) Latest News
Chronic Pain Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 20+ Companies Working in the Domain - GlobeNewswire Inc.
R Squared Ltd Takes Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Moody Aldrich Partners LLC Sells 27,173 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
SG Americas Securities LLC Purchases 8,673 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now - MSN
Merit Financial Group LLC Buys New Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
(ITCI) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now - MSN
StockNews.com Initiates Coverage on Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat
Cantor Fitzgerald Estimates ITCI FY2025 Earnings - Defense World
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews - Benzinga
J&J Says Deals Likely to Shrink After $14.6B Intra-Cellular Buy - BioSpace
Intra-Cellular Therapies (NASDAQ:ITCI) Given "Sector Perform" Rating at Royal Bank of Canada - MarketBeat
J&J’s Intra-Cellular deal could signal more mega-mergers for 2025 - Chemistry World
Barlow Wealth Partners Inc. Purchases Shares of 2,200 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Johnson & Johnson acquires Intra-Cellular Therapies - Pf Media
Research Analysts Issue Forecasts for ITCI FY2025 Earnings - MarketBeat
RBC Capital cuts Intra-Cellular stock rating, hikes target to $132 - MSN
Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSEENFN), Intra-Cellular Therapies, Inc. (NasdaqITCI), H&E Equipment Services, Inc. (NasdaqHEES), Shutterstock, Inc. (NYSE - GlobeNewswire Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, OMIC, ITCI, CCNE on Behalf of Shareholders - Morningstar
Intra-Cellular Therapies Enters Merger Agreement with Johnson & Johnson - Defense World
Johnson & Johnson to acquire Intra-Cellular Therapies - Scientist Live
Avanza Fonder AB Buys New Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales - MSN
Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week’s Rally - MSN
Oak Ridge Investments LLC Boosts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
J&J to buy Intra-Cellular Therapies for $14.6 billion - MSN
Assenagon Asset Management S.A. Has $12.20 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Jim Cramer on Intra-Cellular Therapies, Inc. (ITCI): ‘Intra-Cellular Had Something’ - Insider Monkey
Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires - Insider Monkey
J&J to Acquire Intra-Cellular for About $14.6 Billion - MSN
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer - MSN
Johnson & Johnson pays $14.6 billion for mental health biopharma company - DOTmed HealthCare Business News
Is Johnson & Johnson Stock Set to Reward Long-Term Holders? - Benzinga
Intra-Cellular Therapies acquisition will expand J&J’s presence in neurology space, says GlobalData - Express Pharma
Johnson & Johnson exploring takeover of Intra-CellularBloomberg - MSN
Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains? - MSN
Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal - MSN
J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports - MSN
Why Intra-Cellular (ITCI) Led the Monday Upsurge? - MSN
These Stocks Are Moving the Most Today: Micron, Intra-Cellular Therapies, and More - MSN
J&J to acquire psychiatric drugs maker Intra-Cellular for $14.6 billion - MSN
Intra-Cellular Therapies (NASDAQ:ITCI) Raised to “Strong-Buy” at Cantor Fitzgerald - Defense World
Intra Cellular Therapies Inc Stock (ITCI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
3.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):